Duloxetine Hydrochloride + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Incontinence, Stress
Conditions
Urinary Incontinence, Stress
Trial Timeline
Jan 1, 2003 → Jun 1, 2006
NCT ID
NCT00190996About Duloxetine Hydrochloride + placebo
Duloxetine Hydrochloride + placebo is a phase 3 stage product being developed by Eli Lilly for Urinary Incontinence, Stress. The current trial status is completed. This product is registered under clinical trial identifier NCT00190996. Target conditions include Urinary Incontinence, Stress.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00673452 | Approved | Completed |
| NCT00536471 | Approved | Completed |
| NCT00422162 | Approved | Completed |
| NCT00408993 | Phase 3 | Completed |
| NCT00406848 | Approved | Completed |
| NCT00244296 | Approved | Completed |
| NCT00191919 | Phase 3 | Completed |
| NCT00122863 | Phase 3 | Completed |
| NCT00122824 | Phase 3 | Completed |
| NCT00190996 | Phase 3 | Completed |
| NCT00058968 | Phase 3 | Completed |
Competing Products
20 competing products in Urinary Incontinence, Stress